Graham Warren to Pancreatic Neoplasms
This is a "connection" page, showing publications Graham Warren has written about Pancreatic Neoplasms.
Connection Strength
0.110
-
A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent. Cancer Chemother Pharmacol. 2017 Sep; 80(3):497-505.
Score: 0.110
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.